Simulations Plus, Inc. held a Special Meeting of Shareholders on August 27, 2026, where shareholders approved the Agreement and Plan of Merger with SP Evolution BidCo II, LLC, a subsidiary of Altaris, LLC. The merger proposal received 14,735,712 votes in favor against 771,288 opposed, representing approximately 76.83% of outstanding shares voting. Shareholders also approved non-binding advisory compensation related to the transaction and an adjournment proposal. The closing remains subject to customary conditions, including regulatory approvals in France. Simulations Plus, Inc. develops simulation and modeling software for the pharmaceutical and biotechnology industries.

Simulations Plus, Inc. announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 has expired for its previously disclosed acquisition by Altaris, LLC via SP Evolution HoldCo II, LLC. This expiration satisfies a key regulatory condition required to close the merger transaction. The deal remains subject to customary closing conditions, including shareholder approval and receipt of specific regulatory approvals in France. Management expects the transaction to close in the second half of calendar 2026, pending satisfaction or waiver of remaining conditions. Simulations Plus operates in the pharmaceutical software industry, providing model-informed and AI-accelerated drug development solutions.

Simulations Plus, Inc. issued a press release on July 9, 206, 2026, announcing its financial results for the third quarter ended May 31, 2026. The company also provided supplemental information via an investor presentation. Simulations Plus, Inc. is a provider of scientific and computer modeling software and in vitro testing services for the pharmaceutical and biotechnology industries.

Simulations Plus, Inc. entered into an Agreement and Plan of Merger on June 15, 2026, to be acquired by SP Evolution HoldCo II, LLC, an affiliate of Altaris, LLC, for $18.50 per share in cash. The transaction is subject to shareholder approval and regulatory clearances, with an expected end date of February 10, 2027. The company also established a $3.114 million transaction bonus program for eligible employees, including CEO Shawn O'Connor ($822,000) and CFO William Frederick ($539,000). The company operates in the healthcare and pharmaceutical software industry, providing simulation software and technology-enabled solutions.

Simulations Plus, Inc. entered into a Merger Agreement with SP Evolution HoldCo II, LLC, an affiliate of Altaris, LLC, to be acquired in a transaction where the company will become a wholly owned subsidiary of Parent. The merger will be subject to regulatory approvals and closing conditions. Simulations Plus, Inc. provides software, consulting, and technology-enabled solutions for the pharmaceutical, biotechnology, and medical device industries.